Relationship of soluble RAGE and RAGE ligands HMGB1 and EN-RAGE to endothelial dysfunction in type 1 and type 2 diabetes mellitus

Experimental and Clinical Endocrinology and Diabetes

Volumn 120, Issue 5, 2012, Pages 277-281

  Skrha J ^a,a   Kalousova M ^a   Svarcova J ^a   Muravska A ^a   Kvasnicka J ^a   Landova L ^a   Zima, T ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

diabetes mellitus; endothelial dysfunction; MMPs; RAGE ligands; soluble RAGE

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; CELL ADHESION MOLECULE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GELATINASE B; HEMOGLOBIN A1C; HIGH MOBILITY GROUP B1 PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METALLOPROTEINASE; METFORMIN; ORAL ANTIDIABETIC AGENT; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; ALBUMINURIA; ARTICLE; BLOOD LEVEL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; ENDOTHELIAL DYSFUNCTION; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

ADULT; AGED; CELL ADHESION MOLECULES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; ENDOTHELIUM, VASCULAR; FEMALE; HMGB1 PROTEIN; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; METALLOPROTEASES; MIDDLE AGED; RECEPTORS, IMMUNOLOGIC; S100 PROTEINS; STATISTICS, NONPARAMETRIC; YOUNG ADULT;

EID: 84861460150     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/s-0031-1283161     Document Type: Article

References (36)

1. Bierhaus A, Nawroth PP. Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications. Diabetologia: 2009; 52 2251 2263
2. Biscetti F, Straface G, De Cristofaro R et al. High-mobility group box-1 protein promotes angiogenesis after peripheral ischemia in diabetic mice through a VEGF-dependent mechanism. Diabetes: 2010; 59 1496 1505
3. Gaens KHJ, Ferreira I, van der Kallen CJH et al. Association of polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating RAGE levels. J Clin Endocrinol Metab: 2009; 94 5174 5180
4. Gul OO, Tuncel E, Yilmaz Y et al. Comparative effects of pioglitazone and rosiglitazone on plasma levels of soluble receptor for advanced glycation end products in type 2 diabetes mellitus patients. Metabo-Clin Exp: 2010; 59 64 69
5. Hofmann MA, Drury S, Fu C et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell: 1999; 97 889 901 (Pubitemid 29375048)
6. Jang Y, Kim JY, Kang SM et al. Association of the Gly82Ser polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating levels of soluble RAGE and inflammatory markers in nondiabetic and nonobese Koreans. Metabo-Clin Exp: 2007; 56 199 205 (Pubitemid 46074066)
7. Kadoglou NP, Daskalopoulou SS, Perrea D et al. Matrix metalloproteinases and diabetic vascular complications. Angiology: 2005; 56 173 189 (Pubitemid 40404472)
8. Kalousova M, Bartosova K, Zima T et al. Pregnancy-associated plasma protein A and soluble receptor for advanced glycation end products after kidney transplantation. Kidney Blood Press R: 2007; 30 31 37
9. Kalousova M, Hodkova M, Kazderova M et al. Soluble receptor for advanced glycation end products in patients with decreased renal function. Am J Kidney Dis: 2006; 47 406 411 (Pubitemid 43255173)
10. Kalousova M, Jachymova M, Mestek O et al. Receptor for advanced glycation end products - soluble form and gene polymorphisms in chronic haemodialysis patients. Nephrol Dial Transplant: 2007; 22 2020 2026 (Pubitemid 47244776)
11. Kankova K, Kalousova M, Hertlova M et al. Soluble RAGE, diabetic nephropathy and genetic variability in the AGER gene. Arch Physiol Biochem: 2008; 114 111 119 (Pubitemid 351892711)
12. Katakami N, Matsuhisa M, Kaneto H et al. Serum endogenous secretory RAGE level is an independent risk factor for the progression of carotid atherosclerosis in type 1 diabetes. Atherosclerosis: 2009; 204 288 292
13. Katakami N, Matsuhisa M, Kaneto H et al. Endogenous secretory RAGE but not soluble RAGE is associated with carotid atherosclerosis in type 1 diabetes patients. Diab Vasc Dis Re: 2008; 5 190 197
14. Kosaki A, Hasegawa T, Kimura T et al. Increased plasma S100A12 (EN-RAGE) levels in patients with type 2 diabetes. J Clin Endocr Metab: 2004; 89 5423 5428 (Pubitemid 39518420)
15. Kowluru RA, Kanwar M. Oxidative stress and the development of diabetic retinopathy: Contributory role of matrix metalloproteinase-2. Free Radic Biol Med: 2009; 46 1677 1685
16. Koyama H, Nishizawa Y. AGEs/RAGE in CKD: irreversible metabolic memory road toward CVD? Eur J Clin Invest: 2010; 40 623 635
17. Krechler T, Jachymova M, Mestek O et al. Soluble receptor for advanced glycation end-products (sRAGE) and polymorphisms of RAGE and glyoxalase I genes in patients with pancreas cancer. Clin Biochem: 2010; 43 882 886
18. Marcovecchio ML, Giannini C, Dalton RN et al. Reduced endogenous secretory receptor for advanced glycation end products (esRAGE) in young people with Type 1 diabetes developing microalbuminuria. Diabetic Med: 2009; 26 815 819
19. Nawroth PP, Rudofsky G, Humpert P. Have we understood diabetes? New tasks for diagnosis and therapy. Exp Clin Endocrinol Diabet: 2010; 118 1 3
20. Osawa M, Yamamoto Y, Munesue S et al. De-N-glycosylation or G82S mutation of RAGE sensitizes its interaction with advanced glycation endproducts. BBA-Gen Subjects: 2007; 1770 1468 1474 (Pubitemid 47384994)
21. Papazafiropoulou A, Perrea D, Moyssakis I et al. Plasma levels of MMP-2, MMP-9 and TIMP-1 are not associated with arterial stiffness in subjects with type 2 diabetes mellitus. J Diabetes Complicat: 2010; 24 20 27
22. Raucci A, Cugusi S, Antonelli A et al. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). Faseb J: 2008; 22 3716 3727
23. Schmidt AM, Hori O, Chen JX et al. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest: 1995; 96 1395 1403
24. Skrha J, Prazny M, Hilgertova J et al. Oxidative stress and endothelium influenced by metformin in type 2 diabetes mellitus. Eur J Clin Pharmacol: 2007; 63 1107 1114 (Pubitemid 350112766)
25. Skrha J, Stulc T, Hilgertova J et al. Effect of simvastatin and fenofibrate on endothelium in Type 2 diabetes. Eur J Pharmacol: 2004; 493 183 189 (Pubitemid 38746949)
26. Sparvero LJ, Asafu-Adjei D, Kang R et al. RAGE (receptor for advanced glycation endproducts), RAGE ligands, and their role in cancer and inflammation. J Transl Med: 2009; 7
27. Tam HL, Shiu SWM, Wong Y et al. Effects of atorvastatin on serum soluble receptors for advanced glycation end-products in type 2 diabetes. Atherosclerosis: 2010; 209 173 177
28. Thrailkill KM, Bunn RC, Fowlkes JL. Matrix metalloproteinases: their potential role in the pathogenesis of diabetic nephropathy. Endocrine: 2009; 35 1 10
29. Vazzana N, Santilli F, Cuccurullo C et al. Soluble forms of RAGE in internal medicine. Intern Emerg Med: 2009; 4 389 401
30. Wang LJ, Lu L, Zhang FR et al. Increased serum high-mobility group box-1 and cleaved receptor for advanced glycation endproducts levels and decreased endogenous secretory receptor for advanced glycation endproducts levels in diabetic and non-diabetic patients with heart failure. Eur J Heart Fail: 2011; 13 440 449
31. Wautier JL, Grossin N. sRAGE and esRAGE. Diabetes Metab: 2008; 34 631
32. Yan SF, Du Yan S, Ramasamy R et al. Tempering the wrath of RAGE: An emerging therapeutic strategy against diabetic complications, neurodegeneration, and inflammation. Ann Med: 2009; 41 408 422
33. Yan SF, Ramasamy R, Schmidt AM. Receptor for AGE (RAGE) and its ligands-cast into leading roles in diabetes and the inflammatory response. J Mol Med: 2009; 87 235 247
34. Yan SF, Ramasamy R, Schmidt AM. Soluble RAGE: therapy and biomarker in unraveling the RAGE axis in chronic disease and aging. Biochem Pharmacol: 2010; 79 1379 1386
35. Yan XX, Lu L, Peng WH et al. Increased serum HMGB1 level is associated with coronary artery disease in nondiabetic and type 2 diabetic patients. Atherosclerosis: 2009; 205 544 548
36. Yao D, Brownlee M. Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products (RAGE) and RAGE ligands. Diabetes: 2010; 59 249 255